ERBB2 and breast cancer: Among them, TNBC accounts for about 15% - 20% of breast cancer (4), and compared to hormonal receptor positive or HER2 positive diseases, TNBC is characterized by its highly aggressive clinical progression due to its earlier onset age, greater metastatic potential and worse clinical results (5, 6).